Richter and HRA Pharma in deal on Esmya for Latin America

Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) and France-based Laboratoire HRA Pharma have concluded a sale and purchase agreement in connection with intellectual property rights of ulipristal acetate for the treatment of benign gynecological disorders with respect to the territories of Latin America. No financial terms related to the accord were disclosed.

Following the acquisition of PregLem and its innovative product Esmya (ulipristal acetate) in late 2010, Watson Pharmaceuticals received exclusive licensing rights to develop and market this drug in the USA and in Canada. In December 2011, Richter obtained from HRA Pharma an extension of its geographical scope for Esmya to the Commonwealth of Independent States (CIS) and China, two key markets with a significant growth potential. In June 2013 Richter and HRA Pharma entered into a licensing agreement in connection with marketing rights of ulipristal acetate related to the Latin American region.

“This transaction is considered to be a further strategic move to strengthen Richter’s direct position in Latin America and at the same time to become gradually a global female healthcare player,” said Erik Bogsch, managing director of Richter.